Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a…
Natera Shares Move Lower; Traders Circulate FDA Post ‘Genetic Non-Invasive Prenatal Screening Tests May Have False Results: FDA Safety Communication’
https://www.fda.gov/medical-devices/safety-communications/genetic-non-invasive-prenatal-screening-tests-may-have-false-results-fda-safety-communication
Goldman Sachs Maintains Buy on Natera, Lowers Price Target to $80
Goldman Sachs maintains Natera (NASDAQ:NTRA) with a Buy and lowers the price target from $90 to $80.
Natera, Inc. Highlights Publication Of DEDUCE Study In The Journal of Heart and Lung Transplantation
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that its clinical validation study1 on its donor-derived cell-free DNA (dd-cfDNA) test for the assessment of acute rejection in
Natera Highlights Publication Of Prospera Study In Transplantation Journal
Biopsy-matched study assesses pancreas rejection in the context of a simultaneous kidney-pancreas transplant
AUSTIN, Texas, March 22, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader
$100 Invested In Natera 5 Years Ago Would Be Worth This Much
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 22.16% on an annualized basis.
Natera Highlights Presentation Of Updated Signatera MRD Data From CIRCULATE-Japan Trial
Updated analysis shows 75% detection of recurrence with a single blood draw 4 weeks post surgery
AUSTIN, Texas, March 21, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in